These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 19540640)

  • 1. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
    Sorof J; Berne C; Siewert-Delle A; Jørgensen L; Sager P;
    Diabetes Res Clin Pract; 2006 Apr; 72(1):81-7. PubMed ID: 16246447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study.
    Costacou T; Ellis D; Fried L; Orchard TJ
    Am J Kidney Dis; 2007 Nov; 50(5):721-32. PubMed ID: 17954285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learnt from the 4D trial.
    Wanner C; Krane V
    Nephrol Ther; 2006 Feb; 2(1):3-7. PubMed ID: 16895709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
    N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Shanghai diabetic complications study (SHDCS).
    Jia W; Gao X; Pang C; Hou X; Bao Y; Liu W; Wang W; Zuo Y; Gu H; Xiang K
    Nephrol Dial Transplant; 2009 Dec; 24(12):3724-31. PubMed ID: 19617258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CARDS on the table: should everybody with type 2 diabetes take a statin?
    Lee JD; Morrissey JR; Mikhailidis DP; Patel V
    Curr Med Res Opin; 2005 Mar; 21(3):357-62. PubMed ID: 15811203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan.
    Cheng TY; Wen SF; Astor BC; Tao XG; Samet JM; Wen CP
    Am J Kidney Dis; 2008 Dec; 52(6):1051-60. PubMed ID: 18706747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a reduced estimated glomerular filtration rate a risk factor for stroke in patients with type 2 diabetes?
    Bouchi R; Babazono T; Nyumura I; Toya K; Hayashi T; Ohta M; Hanai K; Kiuchi Y; Suzuki K; Iwamoto Y
    Hypertens Res; 2009 May; 32(5):381-6. PubMed ID: 19325564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial.
    Pijls LT; de Vries H; van Eijk JT; Donker AJ
    Eur J Clin Nutr; 2002 Dec; 56(12):1200-7. PubMed ID: 12494305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.